Last updated: May 25, 2026

Back to directory

Anumana ECG-AI medical AI product profile

Cardiovascular AI platform using standard 12-lead ECGs to surface signals such as low ejection fraction, pulmonary hypertension, and cardiac amyloidosis for clinician follow-up.

Screenshot of the official Anumana ECG-AI product page
Precision medicine and data

Best fit

Health systems evaluating FDA-cleared cardiac detection support that can fit existing ECG, EHR, and cardiology referral workflows.

Primary use case
FDA-cleared ECG-AI algorithms for identifying cardiovascular risk signals from standard 12-lead ECG workflows
Audience
Cardiology, primary care, emergency medicine, health-system innovation, ECG management, and clinical informatics teams
Risk level
High
Pricing signal
Enterprise and health-system pricing; request current algorithm, integration, reimbursement, and regional availability terms.
Official sources
6 official sources

Compare within workflow: Precision medicine and data · comparison shortlist · source index

Regulatory, privacy, evidence, and workflow lens

product-specific source-backed lens: These product-specific signals summarize what the cited sources imply before treating Anumana ECG-AI as safe for a local clinical, operational, or research workflow.

Regulatory / FDAMatch each deployment to the exact cleared algorithm and intended use, including K232699 for low ejection fraction and K252360 for pulmonary hypertension; do not generalize clearance across future or investigational cardiac conditions.
PrivacyReview ECG, EHR, result-routing, audit-log, customer-support, and integration data flows; Anumana says the pulmonary hypertension algorithm runs within the health-system environment, but contract and architecture review still matter.
EvidenceEvaluate local performance by ECG source, patient mix, prevalence, care setting, downstream echo or referral pathway, false-positive burden, and whether published sensitivity and specificity match the intended workflow.
WorkflowBest governed as clinician-reviewed cardiac detection support with defined ECG-system integration, result display, referral criteria, cardiology escalation, monitoring, and patient communication rules.

Where Anumana ECG-AI fits

Anumana describes ECG-AI as a cardiology AI platform that applies FDA-cleared algorithms to standard 12-lead ECGs; FDA records list cleared Anumana ECG-AI algorithms for low ejection fraction and pulmonary hypertension, and Anumana's materials describe health-system workflow integration and U.S. commercial availability for ECG-AI.

Not for: Standalone diagnosis, therapy selection, use outside cleared indications, or deployment without cardiology, primary-care, ECG-system, and informatics governance.

What to verify before using Anumana ECG-AI

Source links

Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.

Related medical AI products

Screenshot of the official Prenosis Sepsis ImmunoScore product page Precision medicine and data

Prenosis Sepsis ImmunoScore

FDA De Novo-authorized AI/ML software that assigns adult emergency department or hospital patients to sepsis risk categories within a clinician-reviewed workflow.

Screenshot of the official Tempus product page Precision medicine and data

Tempus

AI-enabled precision medicine platform spanning molecular testing, multimodal data, clinical assistants, care pathways, imaging insights, and trial matching.

Screenshot of the official SOPHiA GENETICS product page Precision medicine and data

SOPHiA GENETICS

AI-driven precision medicine platform for analyzing complex genomic, radiomic, and multimodal healthcare data.

Screenshot of the official Guardant InfinityAI product page Precision medicine and data

Guardant InfinityAI

Guardant Health AI and machine-learning portfolio for precision oncology data and multimodal real-world evidence workflows.